CL2023000099A1 - Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular - Google Patents
Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisularInfo
- Publication number
- CL2023000099A1 CL2023000099A1 CL2023000099A CL2023000099A CL2023000099A1 CL 2023000099 A1 CL2023000099 A1 CL 2023000099A1 CL 2023000099 A CL2023000099 A CL 2023000099A CL 2023000099 A CL2023000099 A CL 2023000099A CL 2023000099 A1 CL2023000099 A1 CL 2023000099A1
- Authority
- CL
- Chile
- Prior art keywords
- tissue factor
- inflammatory disease
- disease treatment
- antibodies
- factor antibodies
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 3
- 239000000611 antibody drug conjugate Substances 0.000 abstract 4
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 4
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 abstract 1
- 108010000499 Thromboplastin Proteins 0.000 abstract 1
- 102000002262 Thromboplastin Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs for treatment of inflammatory diseases. Also provided herein are methods of treating subjects having inflammatory diseases by administering the anti-TF antibodies or ADCs.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063050629P | 2020-07-10 | 2020-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023000099A1 true CL2023000099A1 (es) | 2023-08-11 |
Family
ID=79552117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023000099A CL2023000099A1 (es) | 2020-07-10 | 2023-01-10 | Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular |
Country Status (13)
Country | Link |
---|---|
US (1) | US20240166765A1 (es) |
EP (1) | EP4178608A1 (es) |
JP (1) | JP2023534191A (es) |
KR (1) | KR20230037042A (es) |
CN (1) | CN116322713A (es) |
AU (1) | AU2021304359A1 (es) |
BR (1) | BR112023000455A2 (es) |
CA (1) | CA3184987A1 (es) |
CL (1) | CL2023000099A1 (es) |
IL (1) | IL299632A (es) |
MX (1) | MX2023000499A (es) |
TW (1) | TW202216198A (es) |
WO (1) | WO2022011324A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023137399A2 (en) * | 2022-01-12 | 2023-07-20 | Iconic Therapeutics Llc | Inflammatory disease treatment using anti-tissue factor antibodies |
WO2023160651A1 (zh) * | 2022-02-24 | 2023-08-31 | 苏州信诺维医药科技股份有限公司 | 一种抗体及其药物偶联物和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001250814B2 (en) * | 2000-03-16 | 2007-02-15 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
US20060104944A1 (en) * | 2004-11-18 | 2006-05-18 | Mousa Shaker A | Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use |
ZA200804082B (en) * | 2005-11-07 | 2010-02-24 | Scripps Research Inst | Compositions and methods for controlling tissue factor signaling specificity |
UA109633C2 (uk) * | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
US8722044B2 (en) * | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
BR112020013679A2 (pt) * | 2018-01-04 | 2020-12-01 | Iconic Therapeutics, Inc. | anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados |
-
2021
- 2021-07-10 CN CN202180054909.3A patent/CN116322713A/zh active Pending
- 2021-07-10 EP EP21836909.8A patent/EP4178608A1/en active Pending
- 2021-07-10 JP JP2023501429A patent/JP2023534191A/ja active Pending
- 2021-07-10 KR KR1020237004394A patent/KR20230037042A/ko unknown
- 2021-07-10 MX MX2023000499A patent/MX2023000499A/es unknown
- 2021-07-10 IL IL299632A patent/IL299632A/en unknown
- 2021-07-10 CA CA3184987A patent/CA3184987A1/en active Pending
- 2021-07-10 BR BR112023000455A patent/BR112023000455A2/pt unknown
- 2021-07-10 WO PCT/US2021/041192 patent/WO2022011324A1/en unknown
- 2021-07-10 US US18/015,532 patent/US20240166765A1/en active Pending
- 2021-07-10 AU AU2021304359A patent/AU2021304359A1/en active Pending
- 2021-07-12 TW TW110125563A patent/TW202216198A/zh unknown
-
2023
- 2023-01-10 CL CL2023000099A patent/CL2023000099A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN116322713A (zh) | 2023-06-23 |
WO2022011324A1 (en) | 2022-01-13 |
JP2023534191A (ja) | 2023-08-08 |
TW202216198A (zh) | 2022-05-01 |
EP4178608A1 (en) | 2023-05-17 |
AU2021304359A1 (en) | 2023-03-02 |
CA3184987A1 (en) | 2022-01-13 |
KR20230037042A (ko) | 2023-03-15 |
BR112023000455A2 (pt) | 2023-03-28 |
MX2023000499A (es) | 2023-04-20 |
US20240166765A1 (en) | 2024-05-23 |
IL299632A (en) | 2023-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000099A1 (es) | Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular | |
PH12020551037A1 (en) | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods | |
CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
CR20220047A (es) | Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados | |
DK1140170T3 (da) | Antistoffragmenter til topisk behandling af öjensygdomme | |
CR10244A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
NO20065227L (no) | Menoklonale antistoff mot hepatocytt vekstfaktor | |
ATE557042T1 (de) | Anti-myostatin-antikörper | |
TN2010000210A1 (en) | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same | |
MX2021010453A (es) | Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos. | |
EA202092518A1 (ru) | Композиции и способы лечения рака | |
EA202190403A1 (ru) | Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство | |
MX2020008208A (es) | Agentes de unión a fibroblastos y uso de estos. | |
BR112022002579A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
JOP20220070A1 (ar) | مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها | |
ATE556134T1 (de) | Mesenchymstammzellen und verwendungendafür | |
PH12020500417A1 (en) | Anti-efgr antibody drug conjugates (adc) and uses thereof | |
EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina | |
EA202092136A1 (ru) | Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства |